\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\ \\:\\ \\ heliotropic\\ rash\\ \\(violaceous\\ rash\\ around\\ the\\ eyelids\\/orbits\\)\ \(0\)\
\-\ labs\ \(154\)\
\-\ \\ \\ ast\\ 105\\ \\(12\\-49\\)\ \(0\)\
\-\ \\ \\ alt\\ 83\\ \\ \\(7\\-56\\)\ \(0\)\
\-\ \\ \\ ck\\ 3617\\ \\(55\\-170\\)\ \(0\)\
\-\ \\ \\ ana\\ screen\\-\\ positive\ \(0\)\
\-\ \\ \\ ana\\ titer\\-\\ 1\\:160\ \(0\)\
\-\ \\ \\ ana\\ pattern\\-\\ peripheral\ \(0\)\
\-\ peripheral\\ ground\\ glass\\ opacities\\ predominantly\\ in\\ the\\ bases\\ of\\ the\\ lungs\\ with\\ some\\ involvement\\ of\\ the\\ anterior\\ apices\\.\\ \\ two\\ nodules\\.\ \(0\)\
\-\ dermatomyositis\ \(6\)\
\-\ hypersensitivity\\ pneumonitis\ \(9\)\
\-\ drug\\ toxicity\ \(1\)\
\-\ usual\\ interstitial\\ pneumonitis\\ \\(uip\\/ipf\\)\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ patient\\ complains\\ of\\ several\\ month\\ history\\ of\\ arthralgias\\ and\\ fatigue\\.\ \(1\)\
\-\ ground\\ glass\\ opacities\\ suggest\\ active\\ inflammation\\.\\ \\ subsequent\\ radiographic\\ follow\\ up\\ may\\ reveal\\ more\\ typical\\ linear\\ interstitial\\ opacities\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ana\\:\\ 0\\.34995798187013416\ \(0\)\
\-\ opacities\\:\\ 0\\.28714355627282384\ \(0\)\
\-\ pneumonitis\\:\\ 0\\.23187046980946502\ \(0\)\
\-\ rash\\:\\ 0\\.21624021711656025\ \(0\)\
\-\ glass\\:\\ 0\\.2016893904011238\ \(0\)\
\-\ ground\\:\\ 0\\.1951818228652855\ \(0\)\
\-\ interstitial\\:\\ 0\\.18176507007976525\ \(0\)\
\-\ heliotropic\\:\\ 0\\.16032362672736658\ \(0\)\
\-\ 3617\\:\\ 0\\.16032362672736658\ \(0\)\
\-\ peripheral\\:\\ 0\\.14337600880031082\ \(0\)\
\-\ arthralgias\\:\\ 0\\.1383069569509946\ \(0\)\
\-\ violaceous\\:\\ 0\\.13036354908890282\ \(0\)\
\-\ ck\\:\\ 0\\.12742765881331425\ \(0\)\
\-\ apices\\:\\ 0\\.12742765881331425\ \(0\)\
\-\ dermatomyositis\\:\\ 0\\.12377850295393497\ \(0\)\
\-\ toxicity\\:\\ 0\\.12170852621729834\ \(0\)\
\-\ hypersensitivity\\:\\ 0\\.11593523490473251\ \(0\)\
\-\ 105\\:\\ 0\\.11159679502945777\ \(0\)\
\-\ usual\\:\\ 0\\.10410857925014538\ \(0\)\
\-\ bases\\:\\ 0\\.10306424296435983\ \(0\)\
\-\ 83\\:\\ 0\\.10176183317756297\ \(0\)\
\-\ fatigue\\:\\ 0\\.09710269977181145\ \(0\)\
\-\ alt\\:\\ 0\\.09639490654976891\ \(0\)\
\-\ ast\\:\\ 0\\.09616517138805361\ \(0\)\
\-\ drug\\:\\ 0\\.09122379798806708\ \(0\)\
\-\ predominantly\\:\\ 0\\.08779134634923384\ \(0\)\
\-\ complains\\:\\ 0\\.08723337918050336\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.08492099184733425\ \(0\)\
\-\ reveal\\:\\ 0\\.08432920227823412\ \(0\)\
\-\ pe\\:\\ 0\\.08287778509243453\ \(0\)\
\-\ suggest\\:\\ 0\\.08143813347456125\ \(0\)\
\-\ linear\\:\\ 0\\.08076024543201152\ \(0\)\
\-\ inflammation\\:\\ 0\\.08057127060463744\ \(0\)\
\-\ around\\:\\ 0\\.08001624059470247\ \(0\)\
\-\ the\\:\\ 0\\.08001505434319464\ \(0\)\
\-\ nodules\\:\\ 0\\.07965572560199614\ \(0\)\
\-\ of\\:\\ 0\\.07847492961581279\ \(0\)\
\-\ typical\\:\\ 0\\.07747705052293116\ \(0\)\
\-\ subsequent\\:\\ 0\\.07589540877990672\ \(0\)\
\-\ active\\:\\ 0\\.07444443078616053\ \(0\)\
\-\ radiographic\\:\\ 0\\.07437823677339689\ \(0\)\
\-\ lungs\\:\\ 0\\.07398622446966958\ \(0\)\
\-\ involvement\\:\\ 0\\.07255964532700625\ \(0\)\
\-\ labs\\:\\ 0\\.06945500946651678\ \(0\)\
\-\ positive\\:\\ 0\\.06606044692801193\ \(0\)\
\-\ several\\:\\ 0\\.06577467657286185\ \(0\)\
\-\ some\\:\\ 0\\.06307713063746229\ \(0\)\
\-\ month\\:\\ 0\\.06098401434565634\ \(0\)\
\-\ two\\:\\ 0\\.05953466531091353\ \(0\)\
\-\ anterior\\:\\ 0\\.055974458369077815\ \(0\)\
\-\ more\\:\\ 0\\.05504867713588419\ \(0\)\
\-\ follow\\:\\ 0\\.05404414718560412\ \(0\)\
\-\ may\\:\\ 0\\.05044960687618825\ \(0\)\
\-\ up\\:\\ 0\\.04959053223035344\ \(0\)\
\-\ history\\:\\ 0\\.03830179383128633\ \(0\)\
\-\ patient\\:\\ 0\\.03260670972160891\ \(0\)\
\-\ in\\:\\ 0\\.024939265712608707\ \(0\)\
\-\ and\\:\\ 0\\.02071570031716995\ \(0\)\
\-\ with\\:\\ 0\\.019630454591889675\ \(0\)\
